Insilico Medicine
PrivateLast Round
IPO
Dec 30, 2025
Est. Valuation
$1.72B
Total Funding Raised
$854.01M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Insilico Medicine is a biotechnology company that develops an advanced AI platform and innovative drugs aimed at providing transformative solutions for cancer, fibrosis, immune disorders, central nervous system diseases, and age-related conditions.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS, Revenue Share
AI Layer
Foundation
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Insilico Medicine Comparables
Compare Insilico Medicine with similar companies based on industry and business-model similarity.
Insilico Medicine Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Dec 30, 2025 | ||||
| Series E | Jun 16, 2025 | ||||
| Series E | Mar 13, 2025 | ||||
| Series E | Jan 7, 2025 | ||||
| Debt | Nov 5, 2024 | ||||
Series D Extension | Aug 11, 2022 |
Key People
Founding team and executive leadership
Insilico Medicine Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Deerfield Management | Series C, Series D Extension |
| AIBasis Fund | Series C |
| Credit Suisse Asset Management | ipo |
| Temasek | ipo |
| Lake Bleu Capital | Series C |
| Winter Capital | Series C |
| 上海浦东创业投资有限公司 | Series E |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 30, 2026
Unified AI framework integrates TargetPro and TargetBench for improved drug development.
- Mar 24, 2026
Partnered with ASKA Pharmaceutical Co., Ltd. for drug discovery.
Recent news
Latest coverage and updates
- attends_eventNov 2, 2026
Insilico Medicine, Inc. is invited to attend the 2026 Future Healthcare Investment Market (FHIM) annual conference in China on Nov 4th '26, where Dr. Feng Ren is set to deliver a keynote on AI-driven small-molecule R&D.
- attends_eventNov 1, 2026
Insilico Medicine, Inc.'s Dr. Jue Wang is invited to attend the China Healthcare Summit in China from Nov 2nd–4th '26 and is scheduled to deliver a keynote on Nov 3rd '26.
- launchesOct 21, 2026
Insilico Medicine, Inc. launches inClinico Agent, an agentic AI workspace that automates clinical trial intelligence and predicts trial outcomes, on Oct 21st '26.
- is_developingOct 17, 2026
Insilico Medicine, Inc. uses AI to develop ISM9528, an experimental non-opioid painkiller for acute and chronic pain that reportedly outperforms morphine in preclinical models; human testing has not yet begun in United Arab Emirates as of Oct 17th '26.
- is_developingSep 9, 2026
Insilico Medicine, Inc. develops experimental drug rentosertib to treat chronic lung diseases and potentially extend lifespan.
Insilico Medicine Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Insilico Medicine's valuation, stock price, and market status.
Is Insilico Medicine a public or private company?
Insilico Medicine is a private company.
What is the current stock price of Insilico Medicine?
Insilico Medicine is a private company, so its shares have no public market price. Caplight tracks Insilico Medicine's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Insilico Medicine worth (valuation)?
Insilico Medicine's valuation is estimated at $1.7B based on funding round data.
Can I buy Insilico Medicine stock?
Insilico Medicine shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Insilico Medicine's last funding round?
Insilico Medicine's most recent funding round was ipo on December 30, 2025.
Who are the main investors in Insilico Medicine?
Key investors in Insilico Medicine include 上海浦东创业投资有限公司, China International Capital Corporation, Morgan Stanley, Aramco Ventures, Value Partners Group.
Will Insilico Medicine IPO soon?
No public IPO plans have been announced for Insilico Medicine.
How can I track Insilico Medicine secondary market activity?
Caplight tracks bids, offers, and trades in Insilico Medicine's shares on secondary markets.